RPG LifeScience.

Has RPG LifeScience. declared dividend?

RPG Life Sciences Ltd has declared a 200% dividend, amounting to ₹16 per share, with an ex-date of June 28, 2024. The company has shown significant total returns over various periods, particularly in the long term, despite a recent short-term decline.

RPG Life Sciences Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 16<BR>- Ex-date: 28 Jun 24<BR><BR>Dividend Yield: 0.74%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.98%, with a dividend return of 0%, resulting in a total return of -2.98%.<BR><BR>Over the past year, the price return was 47.74%, the dividend return was 1.03%, leading to a total return of 48.77%.<BR><BR>In the 2-year period, the price return was 168.65%, the dividend return was 3.07%, culminating in a total return of 171.72%.<BR><BR>For the 3-year period, the price return was 316.33%, with a dividend return of 7.27%, resulting in a total return of 323.6%.<BR><BR>In the last 4 years, the price return was 388.09%, the dividend return was 9.96%, giving a total return of 398.05%.<BR><BR>Over the past 5 years, the price return was 661.83%, with a dividend return of 16.67%, leading to a total return of 678.5%.<BR><BR>Overall, RPG Life Sciences Ltd has declared a substantial dividend, and the total returns over various periods reflect significant growth, particularly in the longer term, despite a recent decline in the short-term price return.

Who are the peers of the RPG LifeScience.?

RPG LifeScience's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Morepen Labs, Orchid Pharma, Advanced Enzyme, and Guj. Themis Bio. Key performance indicators show excellent management risk and growth for Sun Pharma, Cipla, and Dr Reddy's Labs, while RPG LifeScience has below-average growth and a 1-year return of 53.50%.

Peers: RPG LifeScience's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Morepen Labs., Orchid Pharma, Advanced Enzyme, Guj. Themis Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience, Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Advanced Enzyme, and Guj. Themis Bio, while Average management risk is found at Morepen Labs. and Below Average management risk is noted at Orchid Pharma and Panacea Biotec. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at RPG LifeScience, Torrent Pharma, Orchid Pharma, and Panacea Biotec. The Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Morepen Labs., Advanced Enzyme, and Guj. Themis Bio, while Good is noted for Torrent Pharma, and Below Average is found at Orchid Pharma and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while Orchid Pharma has the lowest at -31.48%. RPG LifeScience's own 1-year return is 53.50%, which is significantly higher than Orchid Pharma's but lower than Panacea Biotec's. Additionally, the peers with negative six-month returns include Orchid Pharma, Advanced Enzyme, and Guj. Themis Bio.

Who are in the management team of RPG LifeScience.?

As of March 2018, the management team of RPG LifeScience includes Chairman H V Goenka, Managing Director C T Renganathan, and Company Secretary Rajesh Shirambekar, along with several Non-Executive Independent Directors and a Non-Executive Director, Sachin Nandgaonkar. The team features a mix of executive and non-executive roles.

As of March 2018, the management team of RPG LifeScience includes the following individuals:<BR><BR>1. H V Goenka - Chairman<BR>2. C T Renganathan - Managing Director<BR>3. Rajesh Shirambekar - Company Secretary<BR><BR>Additionally, the board features several Non-Executive Independent Directors:<BR>- C L Jain<BR>- Lalit S Kanodia<BR>- Mahesh S Gupta<BR>- Manoj K Maheshwari<BR>- Narendra Ambwani<BR>- Zahabiya Khorakiwala<BR>- Yugal Sikri<BR><BR>There is also a Non-Executive Director, Sachin Nandgaonkar. <BR><BR>As of March 2018, RPG LifeScience has a diverse management team with a mix of executive and non-executive roles.

What does RPG LifeScience. do?

RPG Life Sciences Ltd manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients. As of March 2025, it reported net sales of ₹1,431 Cr and a net profit of ₹1,174 Cr, with a market cap of ₹4,251 Cr.

Overview:<BR>RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History:<BR>RPG Life Sciences Limited, originally incorporated as Searle India Limited in 1968, underwent a status change when GD Searle withdrew from India in 1993, leading to the RPG Group acquiring its holdings. The company was later incorporated under its current name on March 29, 2007. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,431 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,174 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 4,251 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 46.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.94% <BR>Debt Equity: -0.50 <BR>Return on Equity: 17.95% <BR>Price to Book: 8.00 <BR><BR>Contact Details:<BR>Address: RPG House, 463 Dr Annie Besant Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-24981650 <BR>Email: info@rpglifesciences.com <BR>Website: http://www.rpglifesciences.com

Who are the top shareholders of the RPG LifeScience.?

The top shareholders of RPG LifeScience include Nucleus Life Trust with 53.94%, Authum Investment And Infrastructure Limited at 2.02%, and individual investors holding 15.33%. Additionally, mutual funds hold 3.53%, and 46 foreign institutional investors have a combined stake of 1.45%, with no pledged promoter holdings reported.

The top shareholders of RPG LifeScience include the promoters, with Nucleus Life Trust, managed by Mr. Harsh Vardhan Goenka as a trustee, holding the largest stake at 53.94%. Other significant shareholders include Authum Investment And Infrastructure Limited, which holds 2.02%, and individual investors collectively owning 15.33%. Additionally, the company has mutual funds represented by six schemes, holding 3.53%, and 46 foreign institutional investors (FIIs) with a combined holding of 1.45%. There are no pledged promoter holdings reported.

How big is RPG LifeScience.?

As of 24th July, RPG Life Sciences Ltd has a market capitalization of 4,142.00 Cr, classifying it as a Small Cap company, with recent Net Sales of 653.43 Cr and a Net Profit of 183.24 Cr. Specific values for Shareholder's Funds and Total Assets are not available.

As of 24th July, RPG Life Sciences Ltd has a market capitalization of 4,142.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, RPG Life Sciences reported Net Sales of 653.43 Cr and a Net Profit of 183.24 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period. However, specific values for Shareholder's Funds and Total Assets are not available.

How has been the historical performance of RPG LifeScience.?

RPG LifeScience has shown consistent growth in net sales and profits, with net sales rising from 330.16 Cr in March 2019 to 653.43 Cr in March 2025, and profit after tax increasing from 10.81 Cr to 183.24 Cr in the same period, reflecting strong financial performance and enhanced shareholder value.

Answer:<BR>The historical performance of RPG LifeScience shows a consistent growth trajectory in net sales and profits over the years. <BR><BR>Breakdown:<BR>RPG LifeScience's net sales have increased from 330.16 Cr in March 2019 to 653.43 Cr in March 2025, reflecting a strong upward trend. The total operating income has followed the same pattern, rising from 330.16 Cr in March 2019 to 653.43 Cr in March 2025. The company's operating profit, excluding other income, has also seen significant growth, climbing from 33.56 Cr in March 2019 to 159.65 Cr in March 2025. This is complemented by an increase in profit before tax, which surged from 15.05 Cr in March 2019 to 232.88 Cr in March 2025. The profit after tax has similarly escalated from 10.81 Cr in March 2019 to 183.24 Cr in March 2025, indicating improved profitability. The earnings per share have dramatically increased from 6.54 in March 2019 to 110.8 in March 2025, showcasing enhanced shareholder value. Overall, RPG LifeScience has demonstrated robust financial performance with increasing revenues and profits over the years.

Is RPG LifeScience. overvalued or undervalued?

As of November 7, 2025, RPG LifeScience is fairly valued with a PE Ratio of 35.54, strong operational efficiency indicated by a ROCE of 46.94% and ROE of 21.01%, and has outperformed the Sensex over the last three and five years, making it an attractive investment compared to its peers.

As of 7 November 2025, the valuation grade for RPG LifeScience has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 35.54, an EV to EBITDA of 24.78, and a PEG Ratio of 0.84, indicating a relatively attractive growth potential compared to its price.<BR><BR>In comparison to its peers, RPG LifeScience's PE Ratio is slightly higher than Sun Pharma's 35.17 but significantly lower than Divi's Lab's 71.11, which is categorized as very expensive. Additionally, while Cipla is rated as attractive with a PE of 22.33, RPG LifeScience's strong ROCE of 46.94% and ROE of 21.01% suggest robust operational efficiency. Notably, RPG LifeScience has outperformed the Sensex over the last three and five years, with returns of 174.55% and 559.32%, respectively, reinforcing its competitive position in the market.

Is RPG LifeScience. technically bullish or bearish?

As of December 3, 2025, the technical trend for RPG LifeScience has shifted to mildly bearish, influenced by bearish signals from the MACD, KST, and Bollinger Bands, despite a mildly bullish daily moving average.

As of 3 December 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart, while the KST also shows bearish signals on both time frames. The Dow Theory indicates a mildly bearish stance for both weekly and monthly periods. Although the daily moving averages show a mildly bullish trend, the overall sentiment is dampened by the bearish signals from the Bollinger Bands on the weekly chart and the mildly bearish OBV on the weekly chart. The RSI shows no signals on both weekly and monthly time frames, indicating a lack of momentum. Overall, the combination of these indicators suggests a cautious outlook for RPG LifeScience in the near term.

When is the next results date for RPG Life Sciences Ltd?

The next results date for RPG Life Sciences Ltd is April 29, 2026.

The next results date for RPG Life Sciences Ltd is scheduled for April 29, 2026.

Are RPG Life Sciences Ltd latest results good or bad?

RPG Life Sciences Ltd's latest results show a mixed performance: while net profit increased by 35.11% sequentially to ₹29.90 crore, it declined 14.40% year-on-year, and operating margins fell significantly. Despite a positive stock market reaction, concerns about revenue growth and margin sustainability suggest a cautious outlook.

RPG Life Sciences Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹29.90 crore for Q4 FY26, which reflects a significant sequential increase of 35.11% compared to the previous quarter. This recovery in profit is a positive sign. However, it is important to note that this figure represents a decline of 14.40% year-on-year, indicating challenges in maintaining profitability compared to the same period last year.<BR><BR>In terms of net sales, the company recorded ₹176.89 crore, which is a slight decrease of 1.74% from the previous quarter but shows a modest year-on-year growth of 2.42%. This tepid growth raises concerns about the company's ability to expand its market share effectively.<BR><BR>Operating margins have also come under pressure, with a decline of 350 basis points quarter-on-quarter, reflecting rising costs or pricing pressures. The operating margin stood at 18.56%, which is significantly lower than the previous year's margin of 28.46%.<BR><BR>Despite the positive stock market reaction, with a 10.66% surge following the results, the underlying operational challenges, particularly the reliance on non-operating income for profit growth, suggest that the company may face difficulties in sustaining this momentum. Overall, while there are some positive aspects, the results highlight significant concerns regarding revenue growth and margin sustainability, leading to a cautious outlook.

Should I buy, sell or hold RPG Life Sciences Ltd?

Which are the latest news on RPG LifeScience.?

Why is RPG Life Sciences Ltd falling/rising?

As of 20-May, RPG Life Sciences Ltd's stock price is rising to Rs 2,303.00, driven by strong recent performance and a 14.26% return over the past month, despite a decline in investor participation. The company is net-debt free and has shown consistent long-term growth, making it a fair valuation compared to peers.

As of 20-May, RPG Life Sciences Ltd's stock price is rising, currently at Rs 2,303.00, reflecting a change of 6.6 points or 0.29% increase. This upward movement can be attributed to several factors. The stock has shown a strong performance over the past month, with a return of 14.26%, significantly outperforming the Sensex, which declined by 4.08% during the same period. Additionally, the stock has consistently generated returns over the last three years, with an impressive 197.03% increase, indicating robust long-term performance.<BR><BR>The company is also net-debt free, which enhances its financial stability. With a return on equity (ROE) of 18.6 and a price-to-book value of 6.3, the stock is trading at a fair valuation compared to its peers. Furthermore, the stock's profits have risen by 18% over the past year, contributing to a positive price-earnings growth (PEG) ratio of 1.9, suggesting that the stock is reasonably priced relative to its earnings growth.<BR><BR>However, it is important to note that there are some negative indicators, such as a decline in investor participation, with delivery volume falling by 24.77% against the 5-day average. Despite this, the stock's performance today is inline with its sector, and it has touched an intraday high of Rs 2,351.1, reflecting positive market sentiment. Overall, the combination of strong recent performance, fair valuation, and consistent returns contributes to the stock's rising price.